ClinVar Miner

Submissions for variant NM_001130987.2(DYSF):c.4847A>G (p.Glu1616Gly)

gnomAD frequency: 0.00001  dbSNP: rs933715192
Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 4
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
CeGaT Center for Human Genetics Tuebingen RCV000513482 SCV000608946 uncertain significance not provided 2017-04-01 criteria provided, single submitter clinical testing
Labcorp Genetics (formerly Invitae), Labcorp RCV000822123 SCV000962910 uncertain significance Qualitative or quantitative defects of dysferlin 2022-08-09 criteria provided, single submitter clinical testing This sequence change replaces glutamic acid, which is acidic and polar, with glycine, which is neutral and non-polar, at codon 1577 of the DYSF protein (p.Glu1577Gly). This variant is present in population databases (no rsID available, gnomAD 0.03%). This variant has not been reported in the literature in individuals affected with DYSF-related conditions. ClinVar contains an entry for this variant (Variation ID: 444504). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is not expected to disrupt DYSF protein function. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance.
Ambry Genetics RCV004975602 SCV005571586 uncertain significance Inborn genetic diseases 2024-10-06 criteria provided, single submitter clinical testing The c.4730A>G (p.E1577G) alteration is located in exon 43 (coding exon 43) of the DYSF gene. This alteration results from a A to G substitution at nucleotide position 4730, causing the glutamic acid (E) at amino acid position 1577 to be replaced by a glycine (G). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear.
Natera, Inc. RCV001834648 SCV002082345 uncertain significance Autosomal recessive limb-girdle muscular dystrophy type 2B 2020-09-03 no assertion criteria provided clinical testing

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.